Mean platelet volume and mean platelet volume to platelet count ratio as predictors of severity and mortality in sepsis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 03 03 2021
accepted: 21 12 2021
entrez: 6 1 2022
pubmed: 7 1 2022
medline: 19 2 2022
Statut: epublish

Résumé

Sepsis is a public health problem due to its high prevalence and mortality. Mean platelet volume (MPV), a biomarker reported in routine blood counts, has been investigated and shows promise for determining fatal outcomes in septic patients. Evaluate whether the mean platelet volume (MPV) and mean platelet volume-to-platelet count (MPV/P) ratio are predictors of clinical severity and mortality in patients with sepsis. A prospective population cohort of 163 patients aged 18-97 years was recruited at the Intensive Care Unit of Pablo Arturo Hospital, Quito, Ecuador from 2017-2019 and followed up for 28 days. Patients were diagnosed with sepsis based on SEPSIS-3 septic shock criteria; in which the MPV and the MPV/P ratio were measured on days 1, 2, and 3. Sequential organ failure assessment (SOFA) score and presence of septic shock assessed clinical severity. Mortality on day 28 was considered the fatal outcome. The average age of the patients was 61,15 years (SD 20,94) and female sex was predominant. MPV cutoff points at days 1, 2 and 3 were >9,45fL, >8,95fL and >8, 85fL; and (MPV/P) ratio >8, 18, >4, 12 y >3, 95, respectively. MPV at days 2 (9,85fL) and 3 (8,55fL) and (MPV/P) ratio at days 1 (4,42), 2 (4,21), and 3 (8,55), were predictors of clinical severity assessed by septic shock, which reached significance in the ROC curves. MPV and (MPV/P) ratio were also predictors of clinical severity determined by SOFA at days 1, 2, and 3, where higher values were observed in non-survivors reaching significance in all categories. MPV and MPV/P ratio at days 1, 2 and 3 were independent predictor factors of mortality using Cox proportional hazards model (HR 2,31; 95% CI 1,36-3,94), (HR 2,11; 95% CI 1,17-3,82), (HR 2,13; 95% CI 1,07-4,21) and (HR 2,38; 95% CI 1,38-4,12), (HR 2,15; 95% CI 1,14-4,06), (HR 4,43; 95% CI, 1,72-11,37) respectively. MPV and the MPV/P ratio are predictors of clinical severity and mortality in sepsis. The MPV and its coefficient are indicators of the biological behavior of platelets in sepsis. They should be considered as a cost-effective and rapidly available tool that guides the treatment.

Identifiants

pubmed: 34990467
doi: 10.1371/journal.pone.0262356
pii: PONE-D-21-06833
pmc: PMC8735631
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0262356

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Mediators Inflamm. 2018 Jul 15;2018:3758068
pubmed: 30116146
Mitochondrion. 2019 Sep;48:16-30
pubmed: 30771504
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053592
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Biomed Res Int. 2016;2016:9060143
pubmed: 27403440
PLoS One. 2019 Oct 17;14(10):e0223553
pubmed: 31622365
Ann Intensive Care. 2014 Jun 27;4:20
pubmed: 25520853
Blood. 2014 Oct 2;124(14):2173-83
pubmed: 25082876
Cell Rep. 2020 May 12;31(6):107615
pubmed: 32402278
Afr Health Sci. 2013 Jun;13(2):333-8
pubmed: 24235932
Thromb Haemost. 2018 Jan;118(1):63-71
pubmed: 29304526
Hematology. 2006 Oct;11(5):317-9
pubmed: 17607580
Crit Care Res Pract. 2016;2016:4370834
pubmed: 26966574
Chin Med J (Engl). 2015 Aug 5;128(15):2012-8
pubmed: 26228211
Saudi Med J. 2015 Oct;36(10):1186-90
pubmed: 26446329
J Cell Biol. 2015 May 11;209(3):453-66
pubmed: 25963822
Methods. 2000 Jul;21(3):259-70
pubmed: 10873480
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Jan;26(1):28-32
pubmed: 24506853
Intern Med. 2013;52(13):1487-93
pubmed: 23812196
Br J Haematol. 2014 Apr;165(2):227-36
pubmed: 24499183
J Cell Biol. 2012 Aug 20;198(4):561-74
pubmed: 22908309
Shock. 2017 Mar;47(3):323-330
pubmed: 27504801

Auteurs

Jorge Luis Vélez-Páez (JL)

Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
Centro de Investigación Clínica en Medicina Crítica, Hospital Pablo Arturo Suárez, Quito, Ecuador.

Pedro Legua (P)

Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú.

Pablo Vélez-Páez (P)

Centro de Investigación Clínica en Medicina Crítica, Quito, Ecuador.
Unidad de Terapia Intensiva, Hospital General IESS de Ibarra, Imbabura, Ecuador.

Estefanía Irigoyen (E)

Centro de Investigación Clínica en Medicina Crítica, Hospital Pablo Arturo Suárez, Quito, Ecuador.

Henry Andrade (H)

Unidad de Terapia Intensiva, Hospital General IESS de Ibarra, Imbabura, Ecuador.

Andrea Jara (A)

Unidad de Emergencia, Hospital Básico de Machachi, Pichincha, Ecuador.

Fernanda López (F)

Instituto de Posgrado Medicina Crítica y Terapia Intensiva, Universidad Central del Ecuador, Quito, Ecuador.

Jorge Pérez-Galarza (J)

Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
Instituto de Investigación en Biomedicina, Universidad Central del Ecuador, Quito, Ecuador.

Lucy Baldeón (L)

Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
Instituto de Investigación en Biomedicina, Universidad Central del Ecuador, Quito, Ecuador.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH